Vaccination and multiple sclerosis;Impfen und Multiple Sklerose

Nervenarzt

Volumn 81, Issue 2, 2010, Pages 181-193

  Lobermann M ^a   Winkelmann, A ^a   Reisinger, E C ^a   Zettl, U K ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Disease progression; Multiple sclerosis; Side effects; Vaccination; Vaccine

Indexed keywords

HEPATITIS B VACCINE;

CLINICAL FEATURE; DISEASE COURSE; HOSPITAL PHYSICIAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; RECURRENT DISEASE; REVIEW; RISK FACTOR; TETANUS; TREATMENT INDICATION; VACCINATION;

BACTERIAL VACCINES; DISEASE PROGRESSION; HUMANS; IMMUNE TOLERANCE; IMMUNIZATION, SECONDARY; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; VIRAL VACCINES;

EID: 77249139146     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-009-2865-3     Document Type: Review

References (92)

1. Ahlgren C, Odén A, Torén K, Andersen O (2009) Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations. Acta Neurol Scand 119:313-320
2. Ascherio A, Zhang SM, Hernán MA, et al. (2001) Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 344:327-332
3. Baumhackl U, Franta C, Retzl J, et al. (2003) A controlled trial of tick-borne encephalitis vaccination in patients with multiple sclerosis. Vaccine 21 [Suppl 1]:56-61
4. Bogdanos DP, Mieli-Vergani G, Vergani D (2000) Virus, liver and autoimmunity. Dig Liver Dis 32:440-446
5. Buljevac D, Flach HZ, Hop WC, et al. (2002) Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125:952-960
6. Briggs WA, Rozek RJ, Migdal SD (1980) Influenza vaccination in kidney transplant recipients: cellular and humoral immune responses. Ann Intern Med 92:471-477
7. Cao M, Sasaki O, Yamada A, et al. (1992) Enhancement of the protective effect of inactivated influenza virus vaccine by cytokines. Vaccine 10:238-242
8. Center for Disease Control and Prevention (CDC) (2002) Adverse events associated with 17D-derived yellow fever vaccination - United States, 2001-2002. MMWR Morb Mortal Wkly Rep 51(44):989-993
9. Confavreux C, Suissa S, Saddier P, et al. (2001) Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 344:319-326 (Pubitemid 32107639)
10. Correale J, Fiol M, Gilmore W (2006) The risk of relapses in multiple sclerosis during systemic infections. Neurology 67:652-659
11. Davies K, Woo P (2002) Immunization in rheumatic diseases of childhood: an audit of the clinical practice of british paediatric rheumatology group members and a review of the evidence. Rheumatology 41:937-941
12. De Keyser J (1998) Safety of tetanus vaccination in relapsing-remitting multiple sclerosis. Infection 26:319
13. De Keyser J, Zwanikken C, Boon M (1998) Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J Neurol Sci 159:51-53
14. Dengler TJ, Strnad N, Zimmermann R, et al. (1996) Pneumokokkenimpfung nach Herz- und Lebertransplantation - Immunantworten bei immunsupprimierten Patienten und gesunden Kontrollpersonen. Dtsch Med Wochenschr 121:1519-1525
15. DeStefano F, Verstraeten T, Chen RT (2002) Hepatitis B vaccine and risk of multiple sclerosis. Expert Rev Vaccines 1:461-466
16. DeStefano F, Verstraeten T, Jackson LA, et al. (2003) Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 60:504-509
17. Erlanger TE, Weiss S, Keiser J, et al. (2009) Past, present, and future of Japanese encephalitis. Emerg Infect Dis 15(1):1-7
18. Flachenecker P, Toyka KV, Hartung HP (1995) Aktive Schutzimpfungen bei multipler Sklerose. Dtsch Med Wochenschr 120(44):1513-1516
19. Fraser A, Goldberg E, Acosta CJ, et al. (2007) Vaccines for preventing typhoid fever. Cochrane Database Syst Rev (3):CD001261
20. Fujinami RS, Oldstone MB (1985) Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 230:1043-1045
21. Gelinck L, Teng Y, Rimmelzwaan G, et al. (2007) Poor serological response upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 66 [Suppl II]:160 (Abstr THU0116)
22. Glück T, Müller-Ladner U (2008) Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis 46(9):1459-1465
23. Gold R, Barreto L, Ferro S, et al. (2007) Safety and immunogenicity of a fully liquid vaccine containing five-component pertussis-diphtheria-tetanus- inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccines administered at two, four, six and 18 months of age. Can J Infect Dis Med Microbiol 18:241-248
24. Gout O (2001) Vaccinations and multiple sclerosis. Neurol Sci 22:151-154
25. Hemmer CJ, Littmann M, Loebermann M, et al. (2005) Ein Fall von FSME in Mecklenburg-Vorpommern. Dtsch Med Wochenschr 130:2507-2510
26. Hernán MA, Alonso A, Hernández-Díaz S (2006) Tetanus vaccination and risk of multiple sclerosis: a systematic review. Neurology 67(2):212-225
27. Jefferson T, Heijbel H (2001) Demyelinating disease and hepatitis B vaccination: is there a link? Drug Saf 24:249-254
28. Koerner I, Kochs G, Kalinke U, et al. (2007) Protective role of beta interferon in host defense against influenza A virus. J Virol 81:2025-2030
29. Koff RS (1999) The case for routine childhood vaccination against hepatitis A. N Engl J Med 340:644-645
30. Krueger JG, Ochs HD, Patel P, et al. (2008) Effect of therapeutic integrin (CD11a) blockade with Efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study. J Invest Dermatol 128:2615-2624
31. Kuwert E, Klosterkötter W, Linzenmeier G (1968) Neurological complications following rabies vaccination. Med Klin 63:1326-1328
32. Laribière A, Miremont-Salamé G, Reyre H, et al. (2005) Surveillance of adverse effects during a vaccination campaign against meningitis C. Eur J Clin Pharmacol 61:907-911
33. Leroux-Roels I, Bernhard R, Gérard P, et al. (2008) Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 3:e1665
34. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370:580-589
35. Loebermann M, Kollaritsch H, Ziegler T, et al. (2004) A randomized, open-lable study of the immunogenicity and reactogenicity of three lots of a combined typhoid fever/hepatitis A vaccine in healthy adults. Clin Ther 26:1084-1091
36. Maya R, Gershwin ME, Shoenfeld Y (2008) Hepatitis B Virus (HBV) and Autoimmune Disease. Clin Rev Allergy Immunol 34:85-102
37. Matsui M, Kakigi R, Watanabe S, Kuroda Y (1996) Recurrent demyelinating transverse myelitis in a high titer HBs-antigen carrier. J Neurol Sci 139:235-237
38. Mäkelä A, Nuorti JP, Peltola H (2002) Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics 110:957-963
39. Merelli E, Casoni F (2000) Prognostic factors in multiple sclerosis: role of intercurrent infections and vaccinations against influenza and hepatitis B. Neurol Sci 21(4) [Suppl 2]:853-856
40. Michielsens B, Wilms G, Marchal G, Carton H (1990) Serial magnetic resonance imaging studies with paramagnetic contrast medium: assessment of disease activity in patients with multiple sclerosis before and after influenza vaccination. Eur Neurol 30:258-259
41. Mikaeloff Y, Caridade G, Assi S, et al. (2007) Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS inflammatory demyelination. Brain 130:1105-1110
42. Mikaeloff Y, Caridade G, Rossier M, et al. (2007) Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis. Arch Pediatr Adolesc Med 161:1176-1182 (Pubitemid 350223573)
43. Miller AE, Morgante LA, Buchwald LY, et al. (1997) A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology 48:312-314
44. Miller H, Cendrowski W, Shapira K (1967) Multiple sclerosis and vaccination. Br Med J 2:210-213
45. Mokhtarian F, Shirazian D, Morgante L, et al. (1997) Influenza virus vaccination of patients with multiple sclerosis. Mult Scler 3:243-247
46. Monteyne P, André FE (2000) Is there a causal link between hepatitis B vaccination and multiple sclerosis? Vaccine 18:1994-2001
47. Moriabadi NF, Niewiesk S, Kruse N, et al. (2001) Influenza vaccination in MS: absence of T-cell response against white matter proteins. Neurology 56:938-943
48. Multiple Sclerosis Therapy Consensus Group (MSTCG), Wiendl H, Toyka KV, et al. (2008) Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 255(10):1449-1463
49. Myers LW, Ellison GW, Lucia M, et al. (1977) Swine influenza virus vaccination in patients with multiple sclerosis. J Infect Dis 136:S546-S554
50. Piyasirisilp S, Hemachudha T (2002) Neurological adverse events associated with vaccination. Curr Opin Neurol 15:333-338
51. Plotkin SA, Wiktor T (1978) Rabies vaccination. Annu Rev Med 29:583-591
52. Oren S, Mendelboim M, Brawn Y, et al. (2007) Vaccination against influenza in rheumatoid arthritis patients: the effect of rituximab on the humoral response. Ann Rheum Dis 66 [Suppl II]:363 (Abstr FRI0275)
53. Quast U, Herder C, Zwisler O (1991) Vaccination of patients with encephalomyelitis disseminata. Vaccine 9:228-230
54. Rieckmann P, Moriabadi N, Flachenecker P, Toyka K (2001) Anmerkung zum Beitrag von In: Zipp F, Wandinger KP (Hrsg) Aktuelle Empfehlungen zu Impfungen bei Multipler Sklerose. Nervenarzt 72(12):972
55. Rieckmann P, Toyka KV, Multiple Sclerosis Therapy Consensus Group (2002) Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications, Nervenarzt 73(6):556-563
56. Ristori G, Buzzi MG, Sabatini U, et al. (1999) Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis. Neurology 53:1588-1589
57. RKI (2002) Zur Situation bei wichtigen Infektionskrankheiten Impfpräventable Krankheiten in Deutschland bis zum Jahr 2000. Epidemiol Bull 7:49-57
58. RKI (2007) Fünfjahresinzidenz der Frühsommer- Meningoenzephalitis in Kreisen und Kreisregionen, Deutschland, 2002 bis 2006. Epidemiol Bull 15
59. RKI (2008) Tetanus: Zwei Fallberichte zu Erkrankungen. Epidemiol Bull 24:193-196
60. Ross RT, Cheang M (1997) Common infectious diseases in a population with low multiple sclerosis and varicella occurrence. J Clin Epidemiol 50:337-339
61. Ross RT, Nicolle LE, Cheang M (1997) The varicella zoster virus: a pilot trial of a potential therapeutic agent in multiple sclerosis. J Clin Epidemiol 50(1):63-68
62. Rutschmann OT, McCrory DC, Matchar DB (2002) Immunization Panel of Multiple sclerosis Council for Clinical Practice Guidelines. Immunization and MS: a summary of published evidence and recommendations. Neurology 59:1837-1843
63. Sadovnick AD, Scheifele DW (2000) School-based hepatitis B vaccination programme and adolescent multiple sclerosis. Lancet 355:549-550
64. Salvetti M, Pisani A, Bastianello S, et al. (1995) Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination. J Neurol 242:143-146
65. Sanchez-Fructuoso AI, Prats D, Naranjo P, et al. (2000) Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols. Transplantation 69(3):436-439
66. Schattenfroh C (2004) Akute demyelinisierende Enzephalomyelitis nach aktiver Immunisierung gegen Frühsommer-Meningoencephalitits. Nervenarzt 75:776-779
67. Schattner A (2005) Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 23:3876-3886
68. Schwid SR, Decker MD, Lopez-Bresnahan M for the Rebif Influenza Vaccine Study Investigators (2005) Immune response to influenza vaccine is maintained in patients with MS receiving interferon-beta 1a. Neurology 65(12):1964-11466
69. Shoenfeld Y, Aron-Maor A (2000) Vaccination and autoimmunity- ′vaccinosis′: a dangerous liaison? J Autoimmun 14:1-10
70. Sibley WA, Bamford CR, Laguna JF (1976) Influenza vaccination in patients with multiple sclerosis. JAMA 236:1965-1966
71. Sibley WA, Foley JM (1965) Infection and immunization in multiple sclerosis. Ann N Y Acad Sci 122:457-466
72. Shah I (2008) Acute demyelinating encephalomyelitis due to neural antirabies vaccine. J Travel Med 15:58-59
73. STIKO (2007) Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2007. Epidemiol Bull 30:268-286
74. Süss J, Schrader C, Falk U, Wohanka N (2004) Tick-borne encephalitis (TBE) in Germany - epidemiological data, development of risk areas and virus prevalence in field-collected ticks and in ticks removed from humans. Int J Med Microbiol 293 [Suppl 37]:69-79
75. Sutton I, Lahoria R, Tan I, et al. (2009) CNS demyelination and quadrivalent HPV vaccination. Mult Scler 15:116-119
76. Tauber E, Kollaritsch H, von Sonnenburg F, et al. (2008) Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 198(4):493-499
77. Touzé E, Fourrier A, Rue-Fenouche C, et al. (2002) Hepatitis B vaccination and first central nervous system demyelinating event: a case-control study. Neuroepidemiology 21:180-186
78. Van Damme P, Minervini G, Liss CL, et al. (2009) Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults. Hum Vaccin 5(2):92-97
79. Van der Kolk LE, Baars JW, Prins MH, et al. (2002) Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100(6):2257-2259
80. Veit O, Niedrig M, Chapuis-Taillard C, et al. (2009) Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis 48(5):659-666
81. Versluis DJ, Beyer WE, Masurel N, et al. (1986) Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine. Transplantation 42(4):376-379
82. Verstraeten T, Davis R, DeStefano F (2005) Immunity to tetanus is protective against the development of multiple sclerosis. Med Hypotheses 65:966-969
83. Wagner D, Wagenbreth I, Stachan-Kunstyr R, et al. (1994) Hepatitis B vaccination of immunosuppressed heart transplant recipients with the vaccine Hepa Gene 3 containing pre-S1, pre-S2 and S gene products. Clin Invest 72:350-352
84. Wenzel HH, Jahnel J, Hoegenauer C, et al. (2003) Inadequately low antibodies against the tick-borne encephalitis virus in immunized patients with inflammatory bowel disease and azathioprine treatment. Dig Dis Week Abstr S 1375
85. WHO (2008) Cumulative number of confirmed human cases of avian influenza A/(H5N1) Reported to WHO, 19 June 2008. Online: http://www.who.int/csr/disease/ avian-influenza/country/cases-table-2008-06-19/en/index.html [01.09.2008]
86. WHO (2009) Vaccines for the new influenza A (H1N1). Online: http://www.who.int/csr/disease/swineflu/frequently-asked-questions/ vaccine-preparedness/en/index.html [20.06.2009]
87. Wormser GP (2005) Prevention of Lyme borreliosis. Wien Klin Wochenschr 117:385-391
88. Wu J, Fang HH, Chen JT, et al. (2009) Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clin Infect Dis 48:1087-1095
89. Wucherpfennig KW (2001) Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 108:1097-1104
90. Zipp F, Wandinger KP (2001) Aktuelle Empfehlungen zu Impfungen bei Multipler Sklerose. Nervenarzt 72(10):802-806
91. Zipp F, Weil JG, Einhäupl KM (1999) No increase in demyelinating diseases after hepatitis B vaccination. Nat Med 5:964-965
92. Zuckerman JN (2006) Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol 78:169-177